🚭 Financial incentives may improve smoking cessation among patients referred for #LungCancer screening. In a trial of 3,259 underserved adults, sustained abstinence rates were 8.8% with incentives vs 4.3% with usual care. ▪️@JHartMD | @JAMANetwork 🔗 ascopost.com/news/october-20…

Catch up on the latest #AI in #oncology news: 🔹 @FDA-cleared #BreastCancer risk tool 🔹LLMs in oncology telephone triage 🔹Chatbot improves hereditary #cancerrisk awareness 🎥 Watch this week's brief: ascoai.org/videos/weekly-bri…

🌎 Geographic disparities limit access to #BreastCancer clinical trials. A new study found that 76% of U.S. counties had no active TNBC trials, highlighting significant gaps in research access. 🔹Research from @UTMDAnderson & @ASCO ascopost.com/news/october-20…

🧫 The NRG-BR002 trial found that adding metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic #BreastCancer. ▪️Steven J. Chmura, MD, PhD | @JCO_ASCO ascopost.com/news/october-20…

🖥️ #ASCOAI: Personalized PSA monitoring may improve #ProstateCancer follow-up. An #AI model incorporating PSA kinetics, clinical data showed promising accuracy in identifying recurrence risk after radiotherapy. #ASTRO26 ➡️External validation is underway 🔗 ascoai.org/articles/2026/10/…

📄Experts call for stronger quality-of-life reporting in adjuvant #Cancer trials. New recommendations emphasize measuring clinically meaningful deterioration, duration, & recovery rather than relying on average scores. 🔸Ian Tannock, MD | @TheLancetOncol ascopost.com/news/october-20…

🧠 Updated phase I data show promising survival with bivalent #CARTcell therapy in recurrent #Glioblastoma. Among 18 patients, the median OS was 12 months, with no delayed-onset or unexpected toxicities observed. ▪️@StephenBagleyMD | #ASCO26 🔗 ascopost.com/news/october-20…

📰 Top stories in the October issue of The ASCO Post: 🔹Bivalent #CARTcell therapy in recurrent #glioblastoma 🔹B7-H4–targeted ADCs in #ovariancancer 🔹Evolving treatment options for relapsed #DLBCL 🔹#GLP1 RAs & #BreastCancer risk Explore the issue ➡️ ascopost.com/issues/october-…

📱 #ASCOAI: Personalized digital education may strengthen hereditary #Cancer counseling. The AYA-RISE chatbot improved risk comprehension in young patients using guideline-based content and predefined conversations, not generative #AI. Learn more ➡️ ascoai.org/articles/2026/10/…

🫁 Claudia Henschke, PhD, MD, helped transform #LungCancer screening through pioneering research on early detection with low-dose CT. @RajaFlores reflects on her extraordinary career, scientific legacy, and personal impact. Read the full dedication 👉 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted traditional approval to pembrolizumab (Keytruda) and Keytruda Qlex for previously treated, unresectable or metastatic TMB-H solid tumors (≥13 mut/Mb) with no satisfactory alternatives. 🔗 ascopost.com/news/october-20…

🩻 The phase 3️⃣ RT CHARM trial found that a 3-week course of postmastectomy radiation therapy was safe and noninferior to a 5-week course for reconstruction complications in women with #BreastCancer. 🔹Matthew Poppe, MD of @huntsmancancer | @JCO_ASCO 🔗 ascopost.com/news/october-20…

🫁 At today's 50th I-ELCAP Conference, @AltorkiNasser discussed how early #lungcancer detection is transforming surgical management. By identifying cancers sooner, patients may have more opportunities for surgical resection and potentially curative treatment. #IELCAP

🩸The treatment landscape for relapsed/refractory #DLBCL continues to evolve. At the @NCCN Hem Congress, Jeremy S. Abramson, MD, MMSc, discusses how #CARTcell therapy, bispecific antibodies, and novel combinations are reshaping treatment sequencing. 🔗 ️ ascopost.com/news/october-20…

🥼#ASCOAI: A scoping review identified 5 studies of intraoperative #AI decision support, revealing significant gaps in clinical validation, ethical governance and regulatory reporting. ☑️ Findings highlight challenges in translating AI into surgical care ascoai.org/articles/2026/10/…

📸 Facial image analysis may offer a new approach to #cancerrisk assessment. FAHR-Face, an #AI model, estimates biological age & mortality risk to help inform more personalized treatment decisions. ▪️Raymond Mak, MD & Hugo Aerts, PhD | @LancetDigitalH 🔗 ascopost.com/news/october-20…

🚺 Investigational B7-H4–targeted ADC mocertatug rezetecan (Mo-Rez) demonstrated early activity in phase I BEHOLD-1, with response rates of 62% in platinum-resistant #OvarianCancer, 67% in advanced #EndometrialCancer at higher doses. ▪️Ana Oaknin, MD 🔗 ascopost.com/news/october-20…

🧬A study of more than 240,000 patients across 200+ #communityoncology practices found substantial growth in advanced biomarker testing and novel therapy use for metastatic #BreastCancer and #LungCancer. 🔹 Stephen “Fred” Divers, MD | #ASCOQLTY26 🔗 ascopost.com/news/october-20…

💻 #ASCOAI: A new @FDA-cleared #AI tool could help refine preoperative treatment planning for HR-positive, HER2-negative #BreastCancer. TumorSight Risk combines MRI, pathology, and clinical data to generate a personalized recurrence risk score. 🔗 ascoai.org/articles/2026/10/…

🫁 Which #LungCancer studies from #ASCO26 could influence clinical practice? Apar Kishor Ganti, MD, MS, FASCO (@AparGanti) highlights key findings in targeted therapies, immunotherapy, and emerging treatment strategies for #NSCLC and #SCLC. Learn more ➡️ ascopost.com/news/october-20…